Techera Engineering designs and manufactures high-precision tooling, ground support equipment, and sub-assemblies for the aerospace and defense sectors, serving both government PSUs like HAL and private global OEMs.
The company claims a moat based on specialized 5-axis machining capabilities and high entry barriers in defense; however, negative net margins (-10.5%) and low ROCE (9.9%) suggest a lack of structural pricing power or cost advantage.
Management has aggressively invested in high-end machinery and capacity expansion, resulting in high debt-to-equity and interest coverage concerns. While revenue growth is high, it has not yet translated into consistent bottom-line value for shareholders.
The collapse was driven by a liquidity trap where high-interest debt (15% NCDs) and working capital mismanagement finally choked operations. Despite rapid revenue growth, the company never achieved the scale required to offset its negative margins, and the promoter's habit of treating equity as a personal piggy bank to settle private debts destroyed market confidence. When the interest defaults observed in 2026 became systemic, the high-end machinery was liquidated at pennies on the dollar, proving that expensive equipment is not a moat when the operator lacks financial discipline.
RichFakir rates Techera Engineering India Ltd's business quality as poor — 23/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Techera Engineering India Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Techera Engineering India Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Techera Engineering India Ltd's fair value is about ₹8 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →